drugset / Trial / NCT05908513

NAC Treatment and Outcomes in Patients With Advanced Atherosclerosis and DM

NCT05908513

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Atherosclerosis and diabetes are related to coronary artery disease and peripheral artery disease. The mechanisms are related to increased reactive oxygen species (ROS) formation and inflammatory cytokine secretion. However, simply using antioxidant or anti-inflammatory therapies has no optimal outcomes. On the other hand, N-acetylcysteine (NAC) which has both antioxidant and anti-inflammatory effects could effectively attenuate ROS production and reduce vascular inflammation. Hence, we will investigate the effect of NAC treatment on the outcomes in patients with advanced atherosclerotic heart diseases and patients with diabetes combined with significant peripheral artery disease.

Timeline

Start
2021-10-15
Primary completion
2021-10-15
Completion
2021-10-15

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator N-acetylcysteine Small molecule 600 mg Oral